New PET tracer aims to light up hidden cancers
NCT ID NCT07144085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the body and how well it highlights cancer spots compared to standard imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-FXX489 (NNS309) radiotracer
What this could lead to
If successful, this could lead to a more accurate PET/CT imaging method for detecting tumors and their spread, helping doctors diagnose cancer earlier.
What could go wrong
This is a very early Phase 1 study with only 30 participants, so it is not yet proven to work. The main goal is safety and imaging quality, not treatment, so it may not improve patient outcomes directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••